MedTrace Logo

Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia

NCT00653172 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2009-01-09

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

NXL103

600mg orally twice daily

DRUG

comparator

comparator twice daily

DRUG

NXL103

500mg orally twice daily

Sponsors & Collaborators

  • Novexel Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-06-30
Completion
2008-11-30

Countries

  • Chile
  • Croatia
  • Estonia
  • Germany
  • Peru
  • Poland
  • Romania
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653172 on ClinicalTrials.gov